New hepatitis data highlights need for urgent global response
The WHO Global hepatitis report-2017 indicates that the large majority of these people lack access to life-saving testing and treatment.
In a release to the Ghana News Agency, said as a result of this, millions of people are at risk of a slow progression to chronic liver disease, cancer and death.
Dr Margaret Chan, WHO Director General, said “viral hepatitis is now recognized as a major public health challenge that requires an urgent response. Vaccines and medicines to tackle hepatitis exist, and WHO is committed to helping ensure these tools reach all those who need them.”
It said viral hepatitis caused 1.34 million deaths in 2015, a number comparable to deaths caused by tuberculosis and HIV. But while mortality from tuberculosis and HIV has been declining, deaths from hepatitis are on the increase.
Approximately 1.75 million people were newly infected with HCV in 2015, bringing the global total of people living with Hepatitis C to 71 million.
Although overall deaths from hepatitis are increasing, new infections of HBV are falling, thanks to increased coverage of HBV vaccination among children.
It said globally, 84 percent of children born in 2015 received the three recommended doses of the Hepatitis B vaccine. Between the pre-vaccine era (which, according to the year of introduction can range from the 1980s to the early 2000s) and 2015, the proportion of children under 5 years of age with new infections fell from 4.7 to 1.3 percent.
However, an estimated 257 million people, mostly adults born before the introduction of the HBV vaccine, were living with chronic Hepatitis B infection in 2015.
Epidemics in regions and ‘hotspots’
Hepatitis B levels vary widely across WHO regions with the WHO African Region and WHO Western Pacific Region sharing the greatest burden of 6.1 per cent of population (60 million people) and 6.2 per cent of population (115 million people) respectively.
Today, unsafe injections in health care settings and injecting drug use are considered to be the most common routes of HCV transmissions with WHO African Region: 1 per cent of population (11 million people).
There is currently no vaccine against HCV and access to treatment for HBV and HCV is still low.
WHO’s Global Health Sector Strategy on viral hepatitis aims to test 90 per cent and treat 80 per cent of people with HBV and HCV by 2030.
The report notes that just 9 per cent of all HBV infections and 20 per cent of all HCV infections were diagnosed in 2015. An even smaller fraction – 8 per cent of those diagnosed with HBV infection (1.7 million people) were on treatment, and only 7 per cent of those diagnosed with HCV infection (1.1 million people) had started curative treatment during that year.
HBV infection requires lifelong treatment, and WHO currently recommends the medicine tenofovir, already widely used in HIV treatment. Hepatitis C can be cured within a relatively short time using the highly effective direct-acting antivirals (DAAs).
Dr Gottfried Hirnschall, Director of WHO’s Department of HIV and the Global Hepatitis Programme, said, “We are still at an early stage of the viral hepatitis response, but the way forward looks promising.”
“More countries are making hepatitis services available for people in need – a diagnostic test costs less than $1 and the cure for Hepatitis C can be below $200. But the data clearly highlights the urgency with which we must address the remaining gaps in testing and treatment.”
The WHO’s Global Hepatitis report said despite the existing challenges, some countries are taking successful steps to scale-up hepatitis services.
China achieved high coverage (96 per cent) for the timely birth dose of HBV vaccines, and reached the Hepatitis B control goal of less than 1 per cent prevalence in children under the age of 5 in 2015.
Mongolia improved uptake of hepatitis treatment by including HBV and HCV medicines in its National Health Insurance scheme, which covers 98 per cent of its population. In Egypt, generic competition has reduced the price of a 3-month cure for hepatitis C, from $900 in 2015, to less than $200 in 2016. Today in Pakistan, the same course costs as little as $100.
Improving access to Hepatitis C cure received a boost at the end of March 2017, when WHO prequalified the generic active pharmaceutical ingredient of sofosbuvir. This step will enable more countries to produce affordable hepatitis medicines.
Baseline for elimination
WHO’s Global Hepatitis report aims to provide a starting point for hepatitis elimination by indicating baseline statistics on HBV and HCV infections, including mortality, and coverage levels of key interventions. Hepatitis B and C – the two main types out of five different hepatitis infections – are responsible for 96 per cent of overall hepatitis infection.
WHO and partners will organize two high-profile global initiatives to advocate for an urgent response to viral hepatitis. World Hepatitis Day 2017 will be commemorated on 28 July under the theme “Eliminate hepatitis”.
The World Hepatitis Summit 2017, the principal convention of the global hepatitis community, is being co-organized by WHO, the Government of Brazil and the World Hepatitis Alliance, will be held on 1–3 November 2017 in São Paulo, Brazil.